Results 31 to 40 of about 2,224,846 (160)

Suberoylanilide hydroxamic acid overcomes erlotinib-acquired resistance via phosphatase and tensin homolog deleted on chromosome 10-mediated apoptosis in non-small cell lung cancer

Chinese Medical Journal, 2020
. Background:. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib, are widely used to treat non-small cell lung cancer (NSCLC).
Peng-Fei Wu, Wei-Wei Gao, Cui-Lan Sun, Tai Ma, Ji-Qing Hao, Xiu-Yuan Hao   +5 more
doaj   +1 more source

Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells. [PDF]

PLoS ONE, 2012
Non-small-cell lung cancer harboring epidermal growth factor receptor (EGFR) mutations attains a meaningful response to EGFR-tyrosine kinase inhibitors (TKIs).
Keisuke Tabara, Rina Kanda, Kahori Sonoda, Takuya Kubo, Yuichi Murakami, Akihiko Kawahara, Koichi Azuma, Hideyuki Abe, Masayoshi Kage, Aki Yoshinaga, Tomoko Tahira, Kenshi Hayashi, Tokuzo Arao, Kazuto Nishio, Rafael Rosell, Michihiko Kuwano, Mayumi Ono   +16 more
doaj   +1 more source

C-Src activation mediates erlotinib resistance in head and neck cancer by stimulating c-Met [PDF]

, 2013
Purpose: Strategies to inhibit the EGF receptor (EGFR) using the tyrosine kinase inhibitor erlotinib have been associated with limited clinical efficacy in head and neck squamous cell carcinoma (HNSCC). Co-activation of alternative kinases may contribute
Stabile, Laura P, Grandis, JR, Joyce, Sonali, He, Guoqing, Siegfried, Jill M, Henry, C, Gubish, Christopher T, Grandis, Jennifer R, Joyce, S, Stabile, LP, He, G, Lui, Vivian Wai Yan, Quesnelle, Kelly M, Henry, Cassandra, Siegfried, JM, Thomas, Sufi M, Gubish, CT, Quesnelle, KM, Lui, VWY   +18 more
core   +1 more source

YAP promotes erlotinib resistance in human non-small cell lung cancer cells [PDF]

, 2016
Yes-associated protein (YAP) is a main mediator of the Hippo pathway, which promotes cancer development. Here we show that YAP promotes resistance to erlotinib in human non-small cell lung cancer (NSCLC) cells.
You, Liang, Yang, Cheng-Ta, Hu, Bin, Wang, Yu-Cheng, Zhang, Wen-Qian, Li, Hui, You, Bin, Dai, Yuyuan, Yang, Yi-Lin, Jablons, David M, Hsu, Ping-Chih, Xu, Zhidong, Liu, Shu   +12 more
core   +1 more source

Characterisation and modulation of drug resistance in lung cancer cell lines [PDF]

, 2010
Chemotherapy drug resistance is a major obstacle in the treatment of cancer. It can result from an increase in levels of cellular drug efflux pumps such as P-glycoprotein (P-gp).
Dunne, Gráinne
core   +2 more sources

Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer

BMC Cancer, 2011
Background Patients with advanced or metastatic non-small cell lung cancer (NSCLC) can develop acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib.
Sun Jin, Zhang Zhiyuan, Wang Tongshan, Chen Xiaofen, Guo Renhua, Shu Yongqian   +5 more
doaj   +1 more source

Design, synthesis and biological evaluation of erlotinib-based IDO1 inhibitors

Frontiers in Pharmacology, 2022
Erlotinib is a highly specific and reversible epidermal growth factor receptor tyrosine kinase inhibitor for the targeted therapy of non-small-cell lung cancer (NSCLC) However, the efficacy of erlotinib is limited because the development of drug ...
Xi-xi Hou, Xiao-qing Gong, Long-fei Mao, Ge Sun, Ge Sun, Jian-xue Yang, Jian-xue Yang   +6 more
doaj   +1 more source

Erlotinib-Guided Self-Assembled Trifunctional Click Nanotheranostics for Distinguishing Druggable Mutations and Synergistic Therapy of Nonsmall Cell Lung Cancer

, 2018
The outcome of molecular targeted therapies is restricted by the ambiguous molecular subtypes of nonsmall cell lung cancer (NSCLC), which are difficult to be defined with druggable mutations, and the inevitable emergence of drug-resistance.
Xiaodong Xie, Haijun Chen (580445), Yingying Zhang, Ziying Li, Huijuan Zhang (439573), Yingying Zhang (42910), Fengqiao Li, Yu Gao (69071), Huijuan Zhang, Lu Zhang, Tingting Lv, Ziying Li (2592430), Fengqiao Li (5870084), Yu Gao, Lu Zhang (50563), Lee Jia (409469), Tingting Lv (470075), Lee Jia, Xiaodong Xie (58260), Haijun Chen   +19 more
core   +1 more source

High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer

, 2011
Background: Prior studies highlighted cyclin D1 as a key biomarker of response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors.
William R. Voelzke, Vincent A. Memoli, Voelzke, W., W. Jeffrey Petty, Catherine B. Swift, James J. Urbanic, Konstantin H. Dragnev, Urbanic, J., Lynsay L. Waller, R. Matthew Graham, Memoli, V., Petty, W., Varela, V., Dragnev, K., Victor A. Varela, Waller, L., Graham, Ross, Swift, C.   +17 more
core   +2 more sources

GRHL2-HER3 and E-cadherin mediate EGFR-bypass drug resistance in lung cancer cells

Frontiers in Cell and Developmental Biology
Epidermal growth factor receptor (EGFR) is a major oncogenic protein, and thus EGFR-targeting therapies are widely used in patients with various types of cancer, including lung cancer. However, resistance to EGFR inhibitors, such as erlotinib, presents a
Fumiya Ito, Wakiko Iwata, Yoshihiro Adachi, Hiromi Sesaki, Miho Iijima   +4 more
doaj   +1 more source